Low doses ATLG as GvHD prophylaxis in allogeneic hematopoietic stem cell transplantation for lymphomas
- 9 June 2021
- journal article
- letter
- Published by Springer Science and Business Media LLC in Bone Marrow Transplantation
- Vol. 56 (9), 2295-2298
- https://doi.org/10.1038/s41409-021-01359-x
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Rabbit ATG/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panelBone Marrow Transplantation, 2020
- Low-Dose Anti-T Lymphoglobulin as Prophylaxis for Graft-versus-Host Disease in Unrelated Donor Transplantations for Acute Leukemias and Myelodysplastic SyndromesTransplantation and Cellular Therapy, 2018
- Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti–T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease–Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell TransplantationJournal of Clinical Oncology, 2017
- Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphomaBlood, 2017
- Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donorsBlood, 2016
- Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trialThe Lancet Oncology, 2016
- Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host DiseaseThe New England Journal of Medicine, 2016
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group ReportTransplantation and Cellular Therapy, 2014
- Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trialThe Lancet Oncology, 2009
- CLINICAL MANIFESTATIONS OF GRAFT-VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL-A-MATCHED SIBLING DONOR,STransplantation, 1974